Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Obesity not associated with increased risk for febrile neutropaenia during levofloxacin prophylaxis

03 Sep 2020

Obesity is not a good reason to initiate more aggressive levofloxacin dosing schemes when used for febrile neutropaenia prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.

Adult patients with estimated creatinine clearance ≥50 mL/min receiving their first cycle of a National Comprehensive Cancer Network-defined intermediate-risk regimen were included and evaluated in this single-centre, retrospective cohort study from June 2014 to May 2017.

The primary endpoint of incidence of febrile neutropaenia occurred in 26 patients, of whom 12 (35.3 percent) were obese and 14 (21.9 percent) were nonobese (p=0.16). Six patients (23.1 percent) required intensive care, but no deaths occurred within 30 days of a febrile neutropaenia event.

Obese and nonobese patients showed similar estimated creatinine clearance (median, 97.5 vs 91.8 mL/min; p=0.39), as well as estimated levofloxacin area under the concentration–time curve (median, 85.6 vs 90.8 mg×h/L; p=0.39).

Body weight-related variables, such as total body weight (median 83.4 vs 80.6 kg; p=0.51), body mass index (mean, 29.6 vs 26.8 kg/m2; p=0.35), or body surface area (1.98 vs 1.99 m2; p=0.68), were not significantly associated with febrile neutropaenia in this cohort of patients with similar renal function.

“Levofloxacin given at a standard dose of 500 mg daily is recommended for antibacterial prophylaxis in patients receiving myelosuppressive chemotherapy,” the authors said. “Obese patients have been shown to exhibit enhanced clearance of levofloxacin and may be at risk for prophylactic failure.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.